- BBC NewsNov 06 05:08 AM
Firms still bending the rules, warns former Enron boss
- AsiaOneNov 10 04:08 PM
Former US-based Enron finance chief Andrew Fastow, who served six years' jail for fraud, has told a Singapore audience of his role in one of the biggest corporate scandals in American history. Mr Fastow, 53, speaking pro bono at the Asia-Pacific Fraud Conference last Friday, warned it is the market that will decide if boundary rules have been breached and will show its discomfort through market...
- CNN MoneyNov 05 09:35 AM
The Swiss National Bank owns millions of shares of Valeant Pharmaceuticals, the controversial drug maker accused of fraud.
- rediff.comOct 29 08:29 PM
Dabhol power plant is a lesson on what to avoid while setting up large infrastructure projects.
- rediff.comOct 28 09:30 PM
Dabhol's assets will be demerged into the power plant and the LNG terminal.
- InvestopediaNov 25 07:28 AM
Learn how these must-watch movies for accountants teach about the importance of ethics in a world driven by greed and financial power.
- The GuardianNov 21 04:05 PM
Katherine Soper, winner of the Bruntwood prize, is at the head of a promising group bidding to break down barriers For any British teenage girl hoping to become a playwright, the chances are at last looking rosy. A series of celebrated female dramatists, including creators of hit plays such as Enron , Chimerica and Posh , are now in effect calling out like sirens: “Come on in, the water is ...
- CNN MoneyNov 05 09:14 AM
Switzerland might be known for making precise clocks, but its timing couldn't be worse on at least one investment.
- Benzinga via Yahoo! FinanceNov 02 09:22 AM
Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were higher by 6 percent late Monday morning. Notable short-seller Citron Research said that it will not "dial back warnings" on Valeant. ...
- The Fiscal Times via Yahoo! NewsNov 01 03:15 AM
Shares of Valeant Pharmaceuticals continue to dive after a seething report issued this month by investors betting against the company compared it to Enron and critics questioned its drug-pricing and other business practices. Valeant is just the latest in a string of biotech companies and drug makers to face such high-profile attacks. Since the beginning of the year, investors who bet a stock ...